Life Molecular Imaging is committed to the highest standards of ethical, moral and legal business conduct. Ethical business behaviour is the responsibility of every person in the company and is reflected not only in our relationships with each other but also with our customers, suppliers, clients, contractors, shareholders, and other stakeholders.

Being true to our customers, our environment, and our company, and respecting each other are the fundamental expectations of every Life Molecular Imaging employee and our business partners.

Our culture of compliance, which is fully supported by our senior management, is supported with clear and consistent policies, compliance training, and open communication channels. Life Molecular Imaging has developed its Compliance Program to meet the specific needs of the company and continually assesses the effectiveness of its Compliance Program. We respond quickly to concerns and identify risks, administering corrective action when appropriate.

The Life Healthcare Code of Conduct and related corporate policies are a key component of our commitment to high standards of business and personal ethics.

As member of EFPIA (European Federation of Pharmaceutical Industries Association) Life Molecular Imaging is committed to comply with the EFPIA codes of standard as well as with applicable national laws and regulations for an open and transparent relationship with stakeholders across healthcare including healthcare professionals (HCPs), EU institutions and patient organizations.

Please click for our transparency reporting (as Life Molecular Imaging) for Calendar Year: 2020, 2021, 2022 ,2023, 2024.

Please click for the Spanish transparency reporting (as Life Molecular Imaging) for Calendar Year: 2024

At Life Molecular Imaging we take violations against our Code of Conduct seriously: we thoroughly investigate known cases and take disciplinary actions where appropriate.

Ethics and Compliance Hotline:
Every Life Molecular Imaging representative (including company personnel and agents) has a duty to report any actual or suspected violations of any laws, regulations, government healthcare program requirements, internal policies and procedures, or inappropriate actions.

Employees, customers, business partners, and third parties may make report concerns by contacting the Life Healthcare Ethics Office at ethicsoffice@life.co.za  

All reports submitted to the Integrity Line are handled with discretion. LMI does not tolerate any form of retaliation against individuals who report any suspected improper, unethical or illegal conduct.

We at LMI also engage with our various suppliers around the world to ensure they comply with the general principles of LMI’s Supplier Code of Conduct.

Life Molecular Imaging Global Compliance Program

To obtain a copy of the Compliance Program Document, send an email to: compliance@life-mi.com

Annual Declaration of Compliance

California Compliance Law Statement

Life Molecular Imaging “LMI” is committed to compliance laws and regulations that pertains to its business, sales, research, , and marketing practices in the countries in which LMI operates.  LMI is in compliance with its Compliance Program (CCP) and Cal. Health & Safety Code §§ 119400-119402. Our Compliance Program contains the elements of an effective compliance program identified in the “Compliance Program Guidance for Pharmaceutical Manufacturers” published by the Office of the Inspector General, U.S. Department of Health and Human Services (“HHS-OIG Guidance”). In addition, LMI has adopted the “Code on Interactions with Healthcare Professionals” published by The Pharmaceutical Research and Manufacturers of America (the “PhRMA Code”) and has policies, procedures and processes designed to help ensure compliance with the PhRMA Code.

In accordance with Chapter 8, Part 15, Division 104 of the California Health and Safety Code (§§ 119400-119402), LMI has established an annual aggregate dollar limit of $2,000 per healthcare professional licensed in California for the following items: 1) meals provided in connection with informational presentations or scientific exchange; 2) educational items intended to enhance patient care (excluding items of minimal monetary value and/or of no independent value (e.g. printedadvertising, reimbursement fact sheets)) and items for the benefit of and distribution to patients/care givers.